Skip to main content

SYSTEMATIC REVIEW article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1405147
This article is part of the Research Topic Pleiotropic Effects of Statins: Their Anticoagulant Properties, Clinical and Experimental Data Supporting Their Use in Venous Thromboembolism View all articles

Prevalence and Clinical Characteristics of Venous Thromboembolism in Patients with Lung Cancer: A Systematic Review and Meta-Analysis

Provisionally accepted
Ying Xu Ying Xu Tong Wu Tong Wu *Xue Ren Xue Ren *jing liu jing liu Haibo Zhang Haibo Zhang *Defu Yang Defu Yang *Ying Yan Ying Yan *Dongyang Lv Dongyang Lv *
  • Northern Theater Command General Hospital, Shenyang, China

The final, formatted version of the article will be published soon.

    Background: The prevalence of venous thromboembolism (VTE) is high in patients with cancer and can often present as the first symptom of malignancy. Cancer-associated VTE is one of the most important risk factors contributing to cancer mortality, making its prevention and treatment critical for patients with lung cancer. Methods: We systematically searched for observational studies that estimated the prevalence of VTE in patients with lung cancer. A comprehensive search of electronic databases, including PubMed, EMBASE and Cochrane Library, was systematically conducted from database inception through January 21, 2022. The qualities of included studies were assessed in three domains, including patient selection, comparison, and results. Random effects meta-analyses of the prevalence of VTE in lung cancer were conducted using the metaprop procedure. Chi-square test and I2 value were used to evaluate study heterogeneity. Results: Thirty-five studies involving 742,156 patients were considered eligible for this study. The pooled prevalence of VTE among patients with lung cancer was 5% (95% CI: 0.043-0.056, P = 0.000). The regional prevalence of VTE was 7% (95% CI: 0.06-0.08; I2=99.2%) in North America, 8% (95% CI: 0.06-0.10; I2=97.6%) in Asia, 6% (95% CI: 0.04-0.09; I2=95.9%) in Europe and 11% (95% CI: 0.07-0.15) in Australasia. Conclusions: The prevalence of lung cancer-related VTE is high and region-specific. These results of this review emphasize the importance of understanding the incidence of lung cancer-related VTE and provide argue for for VTE screening of patients with lung cancer.

    Keywords: lung cancer, Venous Thromboembolism, deep vein thrombosis, Pulmonary Embolism, Meta-analysis

    Received: 22 Mar 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Xu, Wu, Ren, liu, Zhang, Yang, Yan and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Tong Wu, Northern Theater Command General Hospital, Shenyang, China
    Xue Ren, Northern Theater Command General Hospital, Shenyang, China
    Haibo Zhang, Northern Theater Command General Hospital, Shenyang, China
    Defu Yang, Northern Theater Command General Hospital, Shenyang, China
    Ying Yan, Northern Theater Command General Hospital, Shenyang, China
    Dongyang Lv, Northern Theater Command General Hospital, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.